Abstract:Reputed as a significant metabolic disorder, non-alcoholic fatty liver disease (NAFLD) is characterized by high fat deposits in the liver and causes substantial economic challenges to any country's workforce. Previous studies have indicated that some lactic acid bacteria may effectively prevent or treat NAFLD. In our previous study, L. acidophilus KLDS1.0901 could prevent chronic alcoholic liver injury and type 2 diabetes in mice by protecting the intestinal barrier and regulating gut microbiota. Thus, we hypothesized that L. acidophilus KLDS1.0901 would possess the ability to alleviate NAFLD. This study aimed to assess the protective effects of L. acidophilus KLDS1.0901 on high-fat diet(HFD)-induced NAFLD. Firstly, hepatic lipid profile and histological alterations were determined to study whether L. acidophilus KLDS1.0901 could ameliorate NAFLD. Then, the intestinal permeability and gut barrier were explored. Finally, gut microbiota was analyzed to elucidate the mechanism from the insights of the gut-liver axis. The results showed that Lactobacillus KLDS1.0901 administration significantly decreased body weight, Lee's index body, fat rate and liver index. L. acidophilus KLDS1.0901 administration significantly improved lipid profiles by decreasing the hepatic levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) and increasing the high-density lipoprotein cholesterol (HDL-C) levels. A conspicuous decrease of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum was observed after L. acidophilus KLDS1.0901 administration. Meanwhile, the H&E and Oil Red O-stained staining showed that L. acidophilus KLDS1.0901 significantly reduced liver lipid accumulation of HFD-fed mice by decreasing the NAS score and lipid area per total area. Our results showed that L. acidophilus KLDS1.0901 administration decreased the interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) concentrations accompanied by the increase of interleukin-10 (IL-10). L. acidophilus KLDS1.0901 administration improves the intestinal barrier function by up-regulating the mRNA levels of Occludin. Claudin-1, ZO-1 and Muc-2, coupled to the decreases of the concentration of LPS and D-lactic acid. Notably, L. acidophilus KLDS1.0901 administration modulated the gut microbiota to near normal pattern. Hence, our results suggested that L. acidophilus KLDS1.0901 can be used as a candidate to ameliorate NAFLD.

Modulation of Gut Microbiota by Glycyrrhizic Acid May Contribute to Its Anti-Nafld Effect in Rats Fed a High-Fat Diet.

Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice

Prevention of Free Fatty Acid-Induced Hepatic Lipotoxicity by 18Beta-Glycyrrhetinic Acid Through Lysosomal and Mitochondrial Pathways.

Prevention of Free Fatty Acids/high Fat Diet‐induced Hepatic Lipotoxicity by 18β Glycyrrhetinic Acid

Yinchen Linggui Zhugan Decoction Ameliorates High Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Modulation of SIRT1/Nrf2 Signaling Pathway and Gut Microbiota.

Effect of Jiangan-Jiangzhi Pill on Gut Microbiota and Chronic Inflammatory Response in Rats with Non-Alcoholic Fatty Liver

Ethanol Extract of Licorice Alleviates HFD-Induced Liver Fat Accumulation in Association with Modulation of Gut Microbiota and Intestinal Metabolites in Obesity Mice

Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet

Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis

Assessing the in vivo ameliorative effects of Lactobacillus acidophilus KLDS1.0901 for induced non-alcoholic fatty liver disease treatment

Chlorogenic Acid and Geniposide Combination Prevents NASH in Rats Fed High-fat Diet Via Microbiota and TLR4-LPS Pathway

Effect of Chinese Herbal Medicine Mixture 919 Syrup on Regulation of the Ghrelin Pathway and Intestinal Microbiota in Rats With Non-alcoholic Fatty Liver Disease

Alanyl-Glutamine Dipeptide Attenuates Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice by Improving Gut Microbiota Dysbiosis

Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation

Regulatory effects of <i>Lactobacillus</i> fermented black barley on intestinal microbiota of NAFLD rats

The Glycyrrhiza Glabra L. Crude Extract Alleviates Lipid Accumulation in NAFLD by Activating Nrf2 and Promoting Autophagy

Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice

Naringin Attenuates High Fat Diet Induced Non-alcoholic Fatty Liver Disease and Gut Bacterial Dysbiosis in Mice

Ginsenoside Rg5 Activates the LKB1/AMPK/mTOR Signaling Pathway and Modifies the Gut Microbiota to Alleviate Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet

The modulation of Luffa cylindrica (L.) Roem supplementation on gene expression and amino acid profiles in liver for alleviating hepatic steatosis via gut microbiota in high-fat diet-fed mice: insight from hepatic transcriptome analysis